Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance.
Sabrina GrasseMatthias LienhardSteffen FreseMartin KerickAnne SteinbachChristina GrimmMichelle HussongJana RolffMichael BeckerFelix DreherUwe SchirmerStefan BoernoAnna RamischGunda LeschberBernd TimmermannChristian GrohéHeike LüdersMartin VingronIduna FichtnerSebastian KleinMargarete OdenthalReinhard BüttnerHans LehrachHolger SültmannRalf HerwigMichal R SchweigerPublished in: Genome medicine (2018)
Using an epigenome-wide sequencing approach, we find differential methylation patterns from primary lung cancer and PDX-derived cancers to be very similar, albeit with a lower degree of differential methylation in primary tumors. We identify LRP12 DNA methylation as a powerful predictive marker for carboplatin resistance. These findings outline a platform for the identification of epigenetic therapy resistance biomarkers based on PDX NSCLC models.